Opioid use disorder (OUD) has become a mounting public health crisis in the US, often disproportionately affecting individuals in the most vulnerable socioeconomic statuses.

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

Bio-Thera Solutions has announced the early termination of its pivotal Phase II/III clinical trial of BAT4406F for NMOSD.

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

egnite has launched the CardioCare Research Suite, an advanced component of its flagship platform, aimed at enhancing patient identification processes for cardiovascular clinical trials. This tool is ...

FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for ROP.

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

Javara has formed a collaboration with Cape Fear Valley Health to enhance clinical trial access for patients in Fayetteville, North Carolina.

OpRegen is a suspension of embryonic stem cell-derived RPE cells restoring visual function in degenerative retinal pathologies.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.